Zobrazeno 1 - 10 of 10 pro vyhledávání: '"C. W. M. van Gils"'
1
Real-world resource use and costs of adjuvant treatment for stage III colon cancer
Autor: S. de Groot, Siok Swan Tan, C. W. M. van Gils, William K. Redekop, C.A. Uyl-de Groot, C.J.A. Punt, Miriam Koopman
Publikováno v: European Journal of Cancer Care. 24:321-332
Since the generalisability of trial-based economic evaluations may be limited, there is an increasing focus on real-world cost-effectiveness. Real-world studies involve evaluating the effects and costs of treatments in daily clinical practice. This s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d124f335925aa9e60253f09a813d226
https://doi.org/10.1111/ecc.12154
Zobrazit plný text záznamu
4
Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck
Autor: Chris P Pescott, M. R. Vergeer, C. W. M. van Gils, Jan Buter, C.A. Uyl-de Groot, N. van der Linden
Publikováno v: van der Linden, N, van Gils, C W M, Pescott, C P, Buter, J, Vergeer, M R & Uyl-de Groot, C A 2015, ' Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck ', European Archives of Oto-Rhino-Laryngology, vol. 272, no. 8, pp. 2007-2016 . https://doi.org/10.1007/s00405-014-3106-3
European Archives of Oto-Rhino-Laryngology, 272(8), 2007-2016. Springer-Verlag
European Archives of Oto-Rhino-Laryngology, 272(8), 2007-2016. Springer Verlag
European archives of oto-rhino-laryngology, 272, 2007-2016. Springer
Clinical trial EMR 62202-006 demonstrates prolonged median locoregional control (24.4 vs. 14.9 months), progression-free survival (17.1 vs. 12.4 months) and overall survival (49.0 vs. 29.3 months) for patients who receive cetuximab added to the compa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c4747edf0dd445ac823c809d09c0c5
https://research.vumc.nl/en/publications/0cf0bead-8e77-4b5f-9452-50c825e6b90e
Zobrazit plný text záznamu
6
Real-world resource use and costs of adjuvant treatment for stage III colon cancer
Autor: C W M, van Gils, S, de Groot, S S, Tan, W K, Redekop, M, Koopman, C J A, Punt, C A, Uyl-de Groot
Publikováno v: European journal of cancer care. 24(3)
Since the generalisability of trial-based economic evaluations may be limited, there is an increasing focus on real-world cost-effectiveness. Real-world studies involve evaluating the effects and costs of treatments in daily clinical practice. This s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d6479b75ea7a27bae67f760dab4362ab
https://pubmed.ncbi.nlm.nih.gov/24372941
Zobrazit plný text záznamu
7
Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results
Autor: Chris P Pescott, Naomi van der Linden, C.A. Uyl-de Groot, Jan Buter, C. W. M. van Gils
Publikováno v: van der Linden, N, van Gils, C W M, Pescott, C P, Buter, J & Uyl-de Groot, C A 2014, ' Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results ', European Archives of Oto-Rhino-Laryngology, vol. 271, no. 6, pp. 1673-1678 . https://doi.org/10.1007/s00405-013-2646-2
European Archives of Oto-Rhino-Laryngology, 271(6), 1673-1678. Springer-Verlag
European Archives of Oto-Rhino-Laryngology, 271(6), 1673-1678. Springer Verlag
In a randomized controlled trial in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), treatment with RT plus cetuximab resulted in improved survival compared to treatment with RT alone. Uncertainty exists about t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01857cd58bd921e7fc0dbd8ae848392
https://doi.org/10.1007/s00405-013-2646-2
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje